Topical NSAIDs: Old Wine in a New Bottle

摘要

Over the past decade, NSAIDs have been on a roller-coaster ride almost as wild as that now being experienced by this country’s housing and financial markets. The selective COX-2 inhibitors—first celecoxib (Celebrex) and then rofecoxib (Vioxx) and valdecoxib (Bextra)—promised to revolutionize the treatment of pain.